ELF3 overexpression as prognostic biomarker for recurrence of stage II colorectal cancer

Ayumi Takaoka; Toshiaki Ishikawa; Satoshi Okazaki; Shuichi Watanabe; Fuyuki Miya; Tatsuhiko Tsunoda; Akifumi Kikuchi; Shinichi Yamauchi; Takatoshi Matsuyama; Masanori Tokunaga; Hiroyuki Uetake; Yusuke Kinugasa

doi:10.21873/INVIVO.12248

ELF3 overexpression as prognostic biomarker for recurrence of stage II colorectal cancer

Ayumi Takaoka, Toshiaki Ishikawa, Satoshi Okazaki, Shuichi Watanabe, Fuyuki Miya, Tatsuhiko Tsunoda, Akifumi Kikuchi, Shinichi Yamauchi, Takatoshi Matsuyama, Masanori Tokunaga, Hiroyuki Uetake, Yusuke Kinugasa

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Background/Aim: Adjuvant chemotherapy for highrisk Stage II colorectal cancer (CRC) is weakly recommended; however, no consensus exists on "high-risk" definition. Prognostic biomarker identification is important for selecting patients with poor prognosis who may benefit from adjuvant chemotherapy. Materials and Methods: Using Microarray data analyses, ELF3 was identified as a candidate gene highly expressed in Stage II CRC with distant recurrences. ELF3 mRNA expression in 168 Stage II CRC patients was subjected to quantitative RT-PCR analysis and ELF3 protein expression in 185 patients was quantified by immunohistochemical analysis. The relationship between mRNA and protein expression levels and patient characteristics were also investigated. Results: The overall recurrence rate and relapsefree survival were significantly poorer in the ELF3 highexpression than the low-expression group at the mRNA and protein levels. High ELF3 mRNA and protein expression levels were independent poor prognostic factors. Conclusion: High ELF3 expression was associated with recurrence of Stage II.

Original language	English
Pages (from-to)	191-201
Number of pages	11
Journal	In Vivo
Volume	35
Issue number	1
DOIs	https://doi.org/10.21873/INVIVO.12248
Publication status	Published - 2021 Jan
Externally published	Yes

Keywords

Biomarker
ELF3
Microarray analysis
Prognostic marker
Stage II colorectal cancer

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Pharmacology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/INVIVO.12248

Cite this

@article{c3817892418e4cdab724e85838201406,

title = "ELF3 overexpression as prognostic biomarker for recurrence of stage II colorectal cancer",

abstract = "Background/Aim: Adjuvant chemotherapy for highrisk Stage II colorectal cancer (CRC) is weakly recommended; however, no consensus exists on {"}high-risk{"} definition. Prognostic biomarker identification is important for selecting patients with poor prognosis who may benefit from adjuvant chemotherapy. Materials and Methods: Using Microarray data analyses, ELF3 was identified as a candidate gene highly expressed in Stage II CRC with distant recurrences. ELF3 mRNA expression in 168 Stage II CRC patients was subjected to quantitative RT-PCR analysis and ELF3 protein expression in 185 patients was quantified by immunohistochemical analysis. The relationship between mRNA and protein expression levels and patient characteristics were also investigated. Results: The overall recurrence rate and relapsefree survival were significantly poorer in the ELF3 highexpression than the low-expression group at the mRNA and protein levels. High ELF3 mRNA and protein expression levels were independent poor prognostic factors. Conclusion: High ELF3 expression was associated with recurrence of Stage II.",

keywords = "Biomarker, ELF3, Microarray analysis, Prognostic marker, Stage II colorectal cancer",

author = "Ayumi Takaoka and Toshiaki Ishikawa and Satoshi Okazaki and Shuichi Watanabe and Fuyuki Miya and Tatsuhiko Tsunoda and Akifumi Kikuchi and Shinichi Yamauchi and Takatoshi Matsuyama and Masanori Tokunaga and Hiroyuki Uetake and Yusuke Kinugasa",

year = "2021",

month = jan,

doi = "10.21873/INVIVO.12248",

language = "English",

volume = "35",

pages = "191--201",

journal = "In Vivo",

issn = "0258-851X",

publisher = "International Institute of Anticancer Research",

number = "1",

}

TY - JOUR

T1 - ELF3 overexpression as prognostic biomarker for recurrence of stage II colorectal cancer

AU - Takaoka, Ayumi

AU - Ishikawa, Toshiaki

AU - Okazaki, Satoshi

AU - Watanabe, Shuichi

AU - Miya, Fuyuki

AU - Tsunoda, Tatsuhiko

AU - Kikuchi, Akifumi

AU - Yamauchi, Shinichi

AU - Matsuyama, Takatoshi

AU - Tokunaga, Masanori

AU - Uetake, Hiroyuki

AU - Kinugasa, Yusuke

PY - 2021/1

Y1 - 2021/1

N2 - Background/Aim: Adjuvant chemotherapy for highrisk Stage II colorectal cancer (CRC) is weakly recommended; however, no consensus exists on "high-risk" definition. Prognostic biomarker identification is important for selecting patients with poor prognosis who may benefit from adjuvant chemotherapy. Materials and Methods: Using Microarray data analyses, ELF3 was identified as a candidate gene highly expressed in Stage II CRC with distant recurrences. ELF3 mRNA expression in 168 Stage II CRC patients was subjected to quantitative RT-PCR analysis and ELF3 protein expression in 185 patients was quantified by immunohistochemical analysis. The relationship between mRNA and protein expression levels and patient characteristics were also investigated. Results: The overall recurrence rate and relapsefree survival were significantly poorer in the ELF3 highexpression than the low-expression group at the mRNA and protein levels. High ELF3 mRNA and protein expression levels were independent poor prognostic factors. Conclusion: High ELF3 expression was associated with recurrence of Stage II.

AB - Background/Aim: Adjuvant chemotherapy for highrisk Stage II colorectal cancer (CRC) is weakly recommended; however, no consensus exists on "high-risk" definition. Prognostic biomarker identification is important for selecting patients with poor prognosis who may benefit from adjuvant chemotherapy. Materials and Methods: Using Microarray data analyses, ELF3 was identified as a candidate gene highly expressed in Stage II CRC with distant recurrences. ELF3 mRNA expression in 168 Stage II CRC patients was subjected to quantitative RT-PCR analysis and ELF3 protein expression in 185 patients was quantified by immunohistochemical analysis. The relationship between mRNA and protein expression levels and patient characteristics were also investigated. Results: The overall recurrence rate and relapsefree survival were significantly poorer in the ELF3 highexpression than the low-expression group at the mRNA and protein levels. High ELF3 mRNA and protein expression levels were independent poor prognostic factors. Conclusion: High ELF3 expression was associated with recurrence of Stage II.

KW - Biomarker

KW - ELF3

KW - Microarray analysis

KW - Prognostic marker

KW - Stage II colorectal cancer

UR - http://www.scopus.com/inward/record.url?scp=85099415137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099415137&partnerID=8YFLogxK

U2 - 10.21873/INVIVO.12248

DO - 10.21873/INVIVO.12248

M3 - Article

C2 - 33402466

AN - SCOPUS:85099415137

SN - 0258-851X

VL - 35

SP - 191

EP - 201

JO - In Vivo

JF - In Vivo

IS - 1

ER -

ELF3 overexpression as prognostic biomarker for recurrence of stage II colorectal cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this